Yüksel Ürün/X
Aug 9, 2025, 19:31
Yüksel Ürün: New EBCTCG Meta-Analysis
Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared on X about a recent paper published on The Lancet:
” New EBCTCG meta-analysis in The Lancet: For postmenopausal women with ER+ early breast cancer who’ve already completed 5 years of endocrine therapy, 5 more years of aromatase inhibitors cut distant recurrence risk by ~25%.
Absolute benefit is greater in N+ disease, but comes with higher fracture risk.”
Title: Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy
More posts featuring Yüksel Ürün.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 25, 2025, 09:45
Aug 25, 2025, 09:09
Aug 24, 2025, 21:47
Aug 24, 2025, 21:22
Aug 24, 2025, 19:46